Skip to content
OpenCapital
Get started

Gossamer Bio, Inc. GOSS Q4 2024 Annual earnings

Reported March 13, 2025 · Before market open

Revenue$9.4MBeat by $2.5MDiluted EPS-$0.15Beat by $0.02
Revenue estimate$6.8M
EPS estimate-$0.17

Next report

Aug 4, 2026 (In 3 weeks)
Revenue estimate$4.3M
EPS estimate-$0.08

Versus estimates

Revenue

Q1 2026$17.0MBeat by $12.3MQ4 2025$13.8MBeat by $6.3MQ3 2025$13.3MBeat by $5.8MQ2 2025$11.5MBeat by $6.1MQ1 2025$9.9MBeat by $5.9M
Q4 2024$9.4MBeat by $2.5M

Diluted EPS

Q1 2026-$0.20Miss by $0.03Q4 2025-$0.21Miss by $0.01Q3 2025-$0.21Miss by $0.02Q2 2025-$0.17Beat by $0.01Q1 2025-$0.16Beat by $0.02
Q4 2024-$0.15Beat by $0.02

Ask the moment Gossamer Bio, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Gossamer Bio, Inc. report Q4 2024 earnings?
Gossamer Bio, Inc. (GOSS) reported Q4 2024 earnings on March 13, 2025 before market open.
What were Gossamer Bio, Inc.'s Q4 2024 revenue and EPS?
Gossamer Bio, Inc. reported revenue of $9.4M and diluted EPS of $-0.15 for Q4 2024.
Did Gossamer Bio, Inc. beat estimates in Q4 2024?
Revenue beat the consensus estimate of $6.8M by $2.5M. EPS beat the consensus estimate of $-0.17 by $0.02.
Where can I find Gossamer Bio, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0001728117-25-000021) directly on SEC EDGAR. The filing index links above go to sec.gov.